PolyMedix to Present Antibiotic Data at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Five Poster Presentations with Results from Antimicrobial Studies Including PolyMedix’s Phase 1B Clinical Trial with PMX-30063

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, will be presenting five posters at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The Conference will take place September 12-15, 2010 at the Boston Convention and Exhibition Center in Boston, MA.

The PolyMedix presentations include the results of a Phase IB study with the company’s novel defensin mimetic antibiotic compound, PMX-30063 against MRSA in human serum. Additionally, results of a preclinical study using PMX-30063 against a panel of foodborne pathogens will also be presented.

The full schedule of Polymedix poster presentations is as follows:

• “Antimicrobial Activities of Structurally Diverse Host Defense Protein Mimics”
  Date/Time: Wednesday, Sept. 15, 9:00AM-11:00AM
  Session: 242 – New Antimicrobial Peptides and Peptidomimetics
  Abstract Number: F1-2086
  Location: Exhibit Hall B1
   
• “Antimicrobial Activities of a Novel Host Defense Protein Mimics Against Foodborne Pathogens”
  Date/Time: Wednesday, Sept. 15, 9:00AM-11:00AM
  Session: 242 – New Antimicrobial Peptides and Peptidomimetics
  Abstract Number: F1-2085
  Location: Exhibit Hall B1
   
• “Antimicrobial Activity in Human Serum After IV Administration of PMX-30063 in a Phase I Study”
  Date/Time: Wednesday, Sept. 15, 9:00AM-11:00AM
  Session: 242 – New Antimicrobial Peptides and Peptidomimetics
  Abstract Number: F1-2083
  Location: Exhibit Hall B1
   
• “In Vitro Antimicrobial Activities of Nonpeptidic Mimics of Host Defense Proteins Against Biowarfare Pathogens”
  Date/Time: Wednesday, Sept. 15, 9:00AM-11:00AM
  Session: 242 – New Antimicrobial Peptides and Peptidomimetics
  Abstract Number: F1-2084
  Location: Exhibit Hall B1
   
• “Population Pharmacokinetics of PMX-30063 After Single and Repeated Intravenous Doses”
  Date/Time: Sunday, Sept. 12, 11:30AM-1:30PM
  Session: 002 – Pharmacology of Oxazolidinones and Miscellaneous Antibacterial Agents
  Abstract Number: A1-025
  Location: Exhibit Hall B1

About ICAAC
The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is an annual event hosted by the American Society for Microbiology and is the premier meeting on infectious diseases. For the past 50 years, the meeting has presented late-breaking scientific information featuring physicians, researchers and other healthcare professionals from around the world fostering solutions for the problem of infectious disease.

About PolyMedix, Inc.
PolyMedix is a publicly traded biotechnology company focused on the development of novel drugs and biomaterials for the treatment of serious acute cardiovascular disorders and infectious diseases. PolyMedix uses a rational drug design approach to create non-peptide small molecule drug candidates and polymers that mimic the activity of proteins. PMX-60056, PolyMedix’s lead heptagonist compound, is being developed to reverse the anticoagulant activity of both heparin and low molecular weight heparins. PolyMedix believes that PMX-60056 could potentially be a safer and easier to use anticoagulant reversing agent, with broader activity, than the currently approved therapy for reversing heparin. PMX-30063, PolyMedix’s lead antibiotic compound, is a small molecule that mimics human host-defense proteins and has a mechanism of action distinct from those of current antibiotic drugs, a mechanism which is intended to make bacterial resistance unlikely to develop. PolyMedix plans to develop this compound for serious systemic Staphylococcal infections, including methicillin resistant Staphylococcus aureus (MRSA). Both PMX-60056 heptagonist and PMX-30063 antibiotic are undergoing clinical testing. PolyMedix also plans to continue the development of its PolyCides™, polymeric formulations as antimicrobial biomaterials, which can be used as additives to paints, plastics, and textiles to create self-sterilizing products and surfaces.

Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause PolyMedix’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. PolyMedix has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements, PolyMedix’s compounds may not successfully complete clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in PolyMedix’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. PolyMedix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Source: Business Wire